Effect of Rosuvastatin on Endothelial Function in Patients With Diabetes and Glaucoma
Status:
Withdrawn
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Endothelial dysfunction can be seen in a variety of vascular related ocular diseases such as
glaucoma or diabetic retinopathy. There is accumulating evidence now that statins may at
least partially improve endothelial function in several vascular beds, an effect that is
probably independent of the lipid lowering effects of the statins.
Consequently, the current study seeks to investigate whether administration of 10 mg
rosuvastatin by mouth (p.o.) for 12 weeks can improve the endothelial function in patients
with glaucoma and diabetic retinopathy. For this purpose, flow mediated vasodilatation of the
brachial artery and flicker induced vasodilatation of retinal vessels will be measured at
baseline, after 6 and 12 weeks of treatment with rosuvastatin.